Tyra Biosciences: Commodore Capital reports 2.48M shares

Tyra Biosciences, Inc. amendment to a Schedule 13G/A reports that Commodore Capital entities and two managing partners beneficially own 2,475,000 shares of Common Stock as of March 31, 2026.

Rhea-AI Filing Summary

Tyra Biosciences, Inc. amendment to a Schedule 13G/A reports that Commodore Capital entities and two managing partners beneficially own 2,475,000 shares of Common Stock as of March 31, 2026. The filing states this equals 4.2% of the class using 59,469,687 shares outstanding as of March 31, 2026.

The report attributes the position to Commodore Capital LP and Commodore Capital Master LP, with Michael Kramarz and Robert Egen Atkinson identified as managing partners exercising investment discretion. The filing is signed and dated May 15, 2026.

Insights

Institutional Ownership Analyst

Commodore Capital reports a passive 4.2% stake in Tyra Biosciences as of March 31, 2026.

Commodore Capital LP and Commodore Capital Master LP are disclosed as the beneficial owners of 2,475,000 shares, with managing partners Michael Kramarz and Robert Egen Atkinson exercising investment discretion. The percentage is calculated versus 59,469,687 shares reported outstanding on March 31, 2026.

Filing type is a Schedule 13G/A (amendment) indicating an institutional investor update; cash‑flow treatment and plans for disposition are not stated in the excerpt. Subsequent filings would be required to reveal any active trading or changes.

Key Figures

Beneficial ownership: 2,475,000 shares Percent of class: 4.2% Shares outstanding (reference): 59,469,687 shares +1 more

4 metrics

Beneficial ownership 2,475,000 shares as of March 31, 2026

Percent of class 4.2% based on 59,469,687 shares outstanding

Shares outstanding (reference) 59,469,687 shares reported in issuer's Form 10-Q as of March 31, 2026

Filing signature date May 15, 2026 date signatures appear on the amendment

Key Terms

Schedule 13G/A, beneficially own, shared dispositive power

3 terms

Schedule 13G/A regulatory

"amendment to a Schedule 13G/A reports that Commodore Capital"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially own regulatory

"may be deemed to beneficially own an aggregate of 2,475,000 shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

shared dispositive power regulatory

"Shared Dispositive Power 2,475,000.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Commodore Capital report in TYRA?

Commodore Capital reports beneficial ownership of 2,475,000 shares of TYRA common stock, equal to 4.2% of the class based on 59,469,687 shares outstanding as of March 31, 2026.

Who is reported as exercising investment discretion for the TYRA holdings?

Michael Kramarz and Robert Egen Atkinson are named as managing partners of Commodore Capital and are reported to exercise investment discretion over the 2,475,000 shares reported.

What is the reporting date and filing date for this Schedule 13G/A?

The beneficial ownership amount is stated as of March 31, 2026 and the Schedule 13G/A amendment is signed and dated May 15, 2026 by the authorized signatories.

Does the filing indicate any plans to sell or buy TYRA shares?

No transaction plans are disclosed in the provided excerpt; the Schedule 13G/A reports beneficial ownership and identifies the holders and managing partners but does not state intentions to acquire or dispose of shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:19 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Tyra Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

90240B106

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Commodore Capital LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,475,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,475,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,475,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Commodore Capital Master LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,475,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,475,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,475,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Robert Egen Atkinson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,475,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,475,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,475,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Michael Kramarz

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,475,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,475,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,475,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tyra Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 2656 State Street, Carlsbad, CALIFORNIA, 92008.
Item 2.
(a)	Name of person filing: Commodore Capital LP Commodore Capital Master LP Robert Egen Atkinson Michael Kramarz Each a "Filer."
(b)	Address or principal business office or, if none, residence: The address for Commodore Capital LP, Robert Egen Atkinson, and Michael Kramarz is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands.
(c)	Citizenship: See Item 4 of the cover page for each Filer.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 90240B106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 of the cover page for each Filer This report on Schedule 13G is being filed by Commodore Capital LP (the "Firm") and Commodore Capital Master LP ("Commodore Master"), Michael Kramarz, and Robert Egen Atkinson. The Firm is the investment manager to Commodore Master. As of March 31, 2026, the Firm may be deemed to beneficially own an aggregate of 2,475,000 shares of Common Stock, $0.0001 par value per share (the "Common Stock"), of Tyra Biosciences, Inc. (the "Issuer"). The Firm, as the investment manager to Commodore Capital Master LP, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 59,469,687 Common Stock reported as issued and outstanding as of March 31, 2026 in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2026.
(b)	Percent of class: See Item 11 of the cover page for each Filer.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 of the cover page for each Filer.
	(ii) Shared power to vote or to direct the vote: See Item 6 of the cover page for each Filer.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 of the cover page for each Filer.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 of the cover page for each Filer.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Commodore Capital LP

Signature:	Michael Kramarz
Name/Title:	Managing Partner
Date:	05/15/2026

Commodore Capital Master LP

Signature:	Michael Kramarz
Name/Title:	Authorized Signatory
Date:	05/15/2026

Robert Egen Atkinson

Signature:	Robert Egen Atkinson
Name/Title:	Authorized Signatory
Date:	05/15/2026

Michael Kramarz

Signature:	Michael Kramarz
Name/Title:	Authorized Signatory
Date:	05/15/2026

Exhibit Information

Exhibit 1: Joint Filing Agreement